Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

Astria Therapeutics, Inc. Logo
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America
ATXS
ATAI Life Sciences N.V. Logo
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America
ATAI
Atea Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America
AVIR
Athira Pharma, Inc. Logo
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America
ATHA
ATOSSA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America
ATOS
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL

Talk to a Data Expert

Have a question? We'll get back to you promptly.